TY  - JOUR
T1  - CYclophosphamide— hemorrhagic cystitis following prolonged low-dose therapy
AU  - Bischel MD
Y1  - 1979/07/20
N1  - 10.1001/jama.1979.03300030014007
JO  - JAMA
SP  - 238
EP  - 239
VL  - 242
IS  - 3
N2  - To the Editor.— 
    Cyclophosphamide (Cytoxan) is a nitrogen mustard derivative that has been extensively used in the treatment of various neoplastic diseases, rheumatoid arthritis, systemic lupus erythematosus, transplantation rejection, and other disorders thought to be benefited by suppression of the immune response.Bladder toxic reaction has been a major factor limiting the usefulness of cyclophosphamide. This problem usually occurs following administration of the drug in high doses (225:605, 1973). Life-threatening blood loss from hemorrhagic cystitis in a patient treated with low doses during a prolonged time interval was unanticipated. The following case suggests that serious bladder damage from cyclophosphamide therapy is related to the cumulative dose, as well as the maintenance dose.Report of a Case.— 
    A 17-year-old girl was treated with cyclophosphamide therapy for a total of 49 months for membranoproliferative glomerulonephritis as the major clinical manifestation of systemic lupus erythematosus. An initial cyclophosphamide dosage of 100 mg/day (2.4 mg/kg)
SN  - 0098-7484
M3  - doi: 10.1001/jama.1979.03300030014007
UR  - http://dx.doi.org/10.1001/jama.1979.03300030014007
ER  -